Diabetology is a continuously evolving discipline, many molecules are developed, and treatment recommendations change regularly according to the latest published studies. After lifestyle measures that must always be preferred before any drug, metformin remains the pharmacological basis of treatment. Current recommendations favor the introduction of an SGLT2 inhibitor or a GLP-1 receptor agonist after metformin because these molecules have shown beneficial cardiovascular and renal effects. The place of the dual GLP-1/GIP agonist is not defined yet. This article guides the physician to choose the most suitable pharmacological treatment for each patient, in the light of the 2024 novelties in the field of diabetes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.53738/REVMED.2025.21.900-1.26 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
What's Going On With Me and How Can I Better Manage My Health? The Potential of GPT-4 to Transform Discharge Letters Into Patient-Centered Letters to Enhance Patient Safety: Prospective, Exploratory Study.
J Med Internet Res
January 2025
Department of Medical Strategy, Process and Quality Management, University Hospital Tübingen, Tübingen, Germany.
Background: For hospitalized patients, the discharge letter serves as a crucial source of medical information, outlining important discharge instructions and health management tasks. However, these letters are often written in professional jargon, making them difficult for patients with limited medical knowledge to understand. Large language models, such as GPT, have the potential to transform these discharge summaries into patient-friendly letters, improving accessibility and understanding.
View Article and Find Full Text PDF[Diabetology : what's new in 2024].
Rev Med Suisse
January 2025
Service d'endocrinologie et diabétologie, Hôpitaux universitaires de Genève, 1211 Genève 14.
Diabetology is a continuously evolving discipline, many molecules are developed, and treatment recommendations change regularly according to the latest published studies. After lifestyle measures that must always be preferred before any drug, metformin remains the pharmacological basis of treatment. Current recommendations favor the introduction of an SGLT2 inhibitor or a GLP-1 receptor agonist after metformin because these molecules have shown beneficial cardiovascular and renal effects.
View Article and Find Full Text PDF[Diabetology: what's new in 2023].
Rev Med Suisse
January 2024
Service d'endocrinologie, diabétologie, nutrition et éducation thérapeutique du patient, Hôpitaux universitaires de Genève, 1211 Genève 14.
Diabetology is a continuously evolving discipline, many molecules are developed and treatment recommendations change often according to the latest published studies. It is therefore often difficult for the primary care physician to be up to date. After lifestyle measures that must always be preferred before any drug, metformin remains the pharmacological basis of treatment.
View Article and Find Full Text PDF[News in diabetology: what's new in 2022].
Rev Med Suisse
January 2023
Service d'endocrinologie, diabétologie, nutrition et éducation thérapeutique du patient, Hôpitaux universitaires de Genève, 1211 Genève 14.
Diabetology is a constantly evolving discipline, many molecules appear on the market and treatment recommendations change quite frequently according to the latest published studies. It is therefore often difficult for the primary care physician to be up to date. After lifestyle measures that must of course be preferred before any drug approach, metformin remains the pharmacological basis of treatment.
View Article and Find Full Text PDFWhat 's the link between otological signs and oral contraception?
Eur J Intern Med
November 2020
Department of Neurosurgery, University Hospital of Limoges, 2, avenue Martin Luther King, 87042 Limoges, France.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!